Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Blood (2024) 144 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2024-201730

Published: 2024

Journal Articles

RNA Methyltransferase Mettl16 Is Indispensable for the Survival of Naïve CD4 + T Cells In Vivo

Daigo Michimata, Hiroki Kato, Naoya Morota, Yuya Tanaka, Kazuki Sakurai, Kazuki Hashimoto, Koichi Onodera, Shunsuke Hatta, Yasushi Onishi, Noriko Fukuhara, Hideo Harigae

Blood (2024) 144 (Supplement 1): 2534.

https://doi.org/10.1182/blood-2024-198338

Published: 2024

Journal Articles

Transcription Factor Gata2 Regulates the Myeloid-Lymphoid Fate Decision in Multipotent Progenitors

Yuya Tanaka, Hiroki Kato, Sayaka Sano, Daigo Michimata, Kazuki Sakurai, Kazuki Hashimoto, Naoya Morota, Koichi Onodera, Shunsuke Hatta, Noriko Fukuhara, Yasushi Onishi, Tohru Fujiwara, Hideo Harigae

Blood (2024) 144 (Supplement 1): 4037.

https://doi.org/10.1182/blood-2024-207236

Published: 2024

Journal Articles

Combined Targeting Patient-Specific Anti-Apoptotic Molecules and CXCR4-Expressing CAR-T Cells Eliminated High-Inflammation State Leukemia with Poor-Prognostic Mutations

Blood (2024) 144 (Supplement 1): 1453.

https://doi.org/10.1182/blood-2024-204989

Published: 2024

Journal Articles

Pyridoxine: beyond a cofactor of ALAS

Tohru Fujiwara, Hideo Harigae

Blood (2024) 144 (13): 1358–1359.

https://doi.org/10.1182/blood.2024025575

Published: 2024

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

Roles for Heme Synthesis in the Maintenance of Hematopoietic Stem and Progenitor Cells

Yan Yan, Hiroki Kato, Sayaka Sano, Eijiro Furukawa, Daigo Michimata, Yuya Tanaka, Kazuki Sakurai, Koichi Onodera, Satoshi Ichikawa, Tohru Fujiwara, Yasushi Onishi, Noriko Fukuhara, Hisayuki Yokoyama, Hideo Harigae

Blood (2023) 142 (Supplement 1): 2682.

https://doi.org/10.1182/blood-2023-174202

Published: 2023

Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Blood (2023) 142 (Supplement 1): 601.

https://doi.org/10.1182/blood-2023-180936

Published: 2023

Journal Articles

Hematopoietic Stem/Progenitor Cell Intrinsic SAM Synthesis Is Required to Prevent p53 Pathway Activation By Maintaining DNA Stability

Eijiro Furukawa, Hiroki Kato, Sayaka Sano, Yan Yan, Daigo Michimata, Yuya Tanaka, Kazuki Sakurai, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Daisuke Saigusa, Tohru Fujiwara, Kazuhiko Igarashi, Hideo Harigae

Blood (2023) 142 (Supplement 1): 4049.

https://doi.org/10.1182/blood-2023-180384

Published: 2023

Journal Articles

Transcription Factor GATA2 Is Inevitable for the Survival and Proper Differentiation of Thymic Multipotent Progenitor Cells By Gene Expression Orchestration

Sayaka Sano, Hiroki Kato, Yan Yan, Eijiro Furukawa, Daigo Michimata, Yuya Tanaka, Kazuki Sakurai, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Tohru Fujiwara, Hideo Harigae

Blood (2023) 142 (Supplement 1): 1182.

https://doi.org/10.1182/blood-2023-178454

Published: 2023

Journal Articles

The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin–transferrin receptor 1 axis

Blood (2023) 142 (4): 352–364.

https://doi.org/10.1182/blood.2022018597

Published: 2023

Includes: Supplemental data

Journal Articles

Altered Transcription By GATA1 Impairs Autophagy and Prevents Ferroptosis in X-Linked Sideroblastic Anemia

Koya Ono, Tohru Fujiwara, Hiroki Shima, Hironari Nishizawa, Chie Suzuki, Noriyuki Takahashi, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Kazuhiko Igarashi, Hideo Harigae

Blood (2022) 140 (Supplement 1): 2467–2468.

https://doi.org/10.1182/blood-2022-163073

Published: 2022

Journal Articles

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Blood (2022) 140 (Supplement 1): 1459–1463.

https://doi.org/10.1182/blood-2022-158024

Published: 2022

Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Blood (2021) 138 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2021-155068

Published: 2021

Journal Articles

Inhibition of S-Adenosylmethionine Synthesis Promotes Erythropoiesis Via Epigenetic Modifications

Hiroki Kato, Nguyen Chi Long, Yusho Ishii, Mitsuyo Matsumoto, Catherine Rhee, Daisuke Saigusa, Ryo Funayama, Hiroaki Okae, Tohru Fujiwara, Akihiko Muto, Hideo Harigae, David T. Scadden, Kazuhiko Igarashi

Blood (2021) 138 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2021-147065

Published: 2021

Journal Articles

Identification of Patient-Specific Anti-Apoptotic Molecules As Therapeutic Targets in Poor Prognosis Acute Lymphoblastic Leukemia (ALL)

Ryo Nakagawa, Yoriko Saito, Shinsuke Takagi, Sadaaki Takata, Hanae Amitani, Mikiko Endo, Naoyuki Uchida, Yukihide Momozawa, Shuichi Taniguchi, Hideo Harigae, Fumihiko Ishikawa

Blood (2021) 138 (Supplement 1): 1236.

https://doi.org/10.1182/blood-2021-147625

Published: 2021

Journal Articles

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Blood (2021) 138 (Supplement 1): 131.

https://doi.org/10.1182/blood-2021-145025

Published: 2021

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Nathan H Fowler, MD, Michael Dickinson, DMed Sci, Martin Dreyling, MD, Joaquin Martinez-Lopez, MD, Arne Kolstad, MD PhD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Monalisa Ghosh, MD, Leslie L. Popplewell, MD FACP, Julio C. Chavez, MD, Emmanuel Bachy, MD PhD, Koji Kato, MD PhD, Hideo Harigae, MD PhD, Marie José Kersten, MD PhD, Charalambos Andreadis, MD, Peter A. Riedell, MD, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), Jose Antonio Pérez-Simón, MD, Sarah J. Nagle, MD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, MD, Piers Patten, MD PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz C. Offner, MD PhD, Andreas Viardot, Professor Dr, Pier Luigi Zinzani, MD, Ram Malladi, MBBS(Lond), MRCP(UK), FRCPath, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD, Aiesha Zia, Stephen J. Schuster, MD, Catherine Thieblemont, MD PhD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138983

Published: 2020

Journal Articles

Proteomic Analysis of Mitochondrial Membrane Protein FAM210B in Erythroid Cells

Chie Suzuki, Tohru Fujiwara, MD PhD, Hiroki Shima, Koya Ono, MD, Kei Saito, Noriko Fukuhara, MD PhD, Yasushi Onishi, MD PhD, Hisayuki Yokoyama, MD PhD, Shinichi Fujimaki, Yukio Nakamura, MD PhD, Hideo Harigae, MD PhD

Blood (2019) 134 (Supplement_1): 3523.

https://doi.org/10.1182/blood-2019-122618

Published: 2019

Journal Articles

Molecular Characterization and Novel Therapeutic Strategy for X-Linked Sideroblastic Anemia Associated with ALAS2 Missense Variants

Koya Ono, MD, Tohru Fujiwara, MD PhD, Kei Saito, MD PhD, Chie Suzuki, Noriyuki Takahashi, Koichi Onodera, MD PhD, Satoshi Ichikawa, MD PhD, Noriko Fukuhara, MD PhD, Yasushi Onishi, MD PhD, Hisayuki Yokoyama, MD PhD, Yukio Nakamura, MD PhD, Hideo Harigae, MD PhD

Blood (2019) 134 (Supplement_1): 3530.

https://doi.org/10.1182/blood-2019-124810

Published: 2019

NARROW

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

RNA Methyltransferase Mettl16 Is Indispensable for the Survival of Naïve CD4 + T Cells In Vivo

Transcription Factor Gata2 Regulates the Myeloid-Lymphoid Fate Decision in Multipotent Progenitors

Combined Targeting Patient-Specific Anti-Apoptotic Molecules and CXCR4-Expressing CAR-T Cells Eliminated High-Inflammation State Leukemia with Poor-Prognostic Mutations

Pyridoxine: beyond a cofactor of ALAS

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Roles for Heme Synthesis in the Maintenance of Hematopoietic Stem and Progenitor Cells

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Hematopoietic Stem/Progenitor Cell Intrinsic SAM Synthesis Is Required to Prevent p53 Pathway Activation By Maintaining DNA Stability

Transcription Factor GATA2 Is Inevitable for the Survival and Proper Differentiation of Thymic Multipotent Progenitor Cells By Gene Expression Orchestration

The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin–transferrin receptor 1 axis

Altered Transcription By GATA1 Impairs Autophagy and Prevents Ferroptosis in X-Linked Sideroblastic Anemia

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Inhibition of S-Adenosylmethionine Synthesis Promotes Erythropoiesis Via Epigenetic Modifications

Identification of Patient-Specific Anti-Apoptotic Molecules As Therapeutic Targets in Poor Prognosis Acute Lymphoblastic Leukemia (ALL)

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Proteomic Analysis of Mitochondrial Membrane Protein FAM210B in Erythroid Cells

Molecular Characterization and Novel Therapeutic Strategy for X-Linked Sideroblastic Anemia Associated with ALAS2 Missense Variants

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only